Decreased HLA-DR+CD3+ T cells three months after allogeneic stem cell transplantation predict severe chronic GvHD and...

Area of Science:

• Immunology
• Transplantation Medicine
• Biomarker Discovery

Background:

• Chronic graft-versus-host disease (cGvHD) is a significant factor in transplant-related mortality (TRM) following allogeneic hematopoietic stem cell transplantation (HSCT).
• Identifying reliable biomarkers for predicting cGvHD and TRM is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the predictive value of peripheral blood activated HLA-DR+CD3+ T cells as a novel biomarker for TRM and cGvHD.
• To determine the correlation between specific counts of activated T cells and the incidence of TRM and cGvHD post-HSCT.

Main Methods:

• Retrospective analysis of 107 patients undergoing allogeneic HSCT.
• Measurement of peripheral blood HLA-DR+CD3+ T cells using flow cytometry at 3 months post-HSCT.
• Statistical correlation analysis between T cell counts and clinical outcomes (TRM, cGvHD).

Main Results:

• A peripheral blood HLA-DR+CD3+ T cell count below 140 cells/µL at 3 months post-HSCT was significantly associated with increased TRM.
• Counts below 100 cells/µL correlated with a higher rate of cGvHD (grade 2-3).
• Subgroup analyses confirmed these associations in patients who received reduced intensity conditioning.

Conclusions:

• Low levels of peripheral blood activated HLA-DR+CD3+ T cells at 3 months post-HSCT may serve as a novel predictive biomarker.
• This biomarker can help identify patients at higher risk for TRM and severe cGvHD.
• Early identification allows for potential intervention and improved management strategies in HSCT recipients.